The advancement of modern biotechnology has enabled biopharmaceutical sector to take center stage soon after the onset of COVID-19 pandemic and save the world from an unprecedented health crisis. The pharmaceutical and biopharmaceutical companies have focused on meeting the surging demand of drugs for the aging population by investing heavily in research and development to deliver remarkable returns. The continuous breakthrough of technology and innovation capability has enabled biopharmaceutical companies to enhance research scale of specialized drugs and become a promising economic sector in near future.
Ology Bio services is one of the highly successful biopharmaceutical companies manufacturing high quality vaccines, proteins, cell & gene therapies, and antibodies. The company is now serving scientific discoveries through innovative solutions and advanced biotechnologies as Resilience with specialization in R&D, process development, and manufacturing of biologics. The state of the art biologics manufacturing facility helps brilliant minds build a resilient tomorrow using advanced technologies. Obtaining US government support has enabled the company to advance medical countermeasures and provide fully integrated services. Moreover, Resilience works with technology providers to provide CDMO services through the obtained funds. They have worked extensively on CGMP manufacturing of bulk drug substances and vaccine delivery technology with a variety of platform expression systems.
1. Biopharmaceutical Expertise
The global pharmaceutical industry is a highly regulated and capital intensive field requiring advanced technology to leverage innovations on large scale. The high tech and knowledge intensive talent expands the opportunities for research on more diseases to put up the pace for improving health standards. The clinical trial procedures are extensively involved to investigate the actual effect of drugs and treatments. Resilience is dedicating the expertise of its highly knowledgeable team members for the development and validation of ligand binding assays.
2. Bioanalytical Services
Resilience has broad experience of analyzing antibody fragments, proteins, antibody drug conjugates, monoclonal and multivalent antibodies for developing ligand binding methods, sample analysis, handling, and management. The comprehensive bioanalytical services has enabled the company to be highly responsive by providing highest quality data and fast turnaround time which eventually made them a reliable drug development partner. The significant expertise of scientists in working with biological products enables them to optimize and validate ligand binding assays in order to meet the requirements of Sponsors.
3. High Risk Biopharmaceuticals
Investing in a new development poses risk of failure. The biopharmaceutical industry has about 5 to 10% success rate for new drugs which is comparatively lower than the intensifying market competition. The biopharmaceutical industry is set up with considerable investment required for research and development of new drugs. The long circle of clinical trials from the beginning to the end of approval process needs development funds depending on the level of difficulty occurred. Resilience is acknowledged as a reputable biopharmaceutical company having core capabilities to use proprietary platform technologies to deliver best products for their partners. The Florida capacity and California Capacity is built with multi purpose and multi product biologics to thrive rapidly in the high tech biotechnology industry.
